Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement
Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The use of ISB in patients undergoing total shoulder arthroplasty (TSA) is the gold standard
and results in significantly reduced pain scores and opioid use. However, patients still have
pain and the majority require opioids postoperatively as the interscalene block (ISB) doesn't
cover all of the dermatomes impacted during TSA. A pectoserratus block typically provides
coverage to additional dermatomes that are impacted during TSA. Currently ISB is performed
for every patient and perform a pectoserratus block to a portion of our patients undergoing
TSA. The purpose of the study is to determine if the addition of the pectoserratus block to
the ISB will results in improvement in pain control and decrease in opioid use, among
patients undergoing TSA. This is a randomized prospective controlled trial. All patients
undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty aged 18-85 will
be considered eligible for the study. Participants will be randomized to one of 2 treatment
groups. Group 1 will receive an ultrasound guided pectoserratus block with 25 mL of 0.25%
bupivacaine. Group 2 will be the control and receive an ultrasound guided pectoserratus block
with 25 mL of saline. The drug will be administered by the anesthesiologist in-charge of the
participant's care or an anesthesiologist who is a part of the study team.